MedTrace Logo

Thymoglobulin in Cadaver Donor

NCT01939171 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-09-11

No results posted yet for this study

Summary

To determine the efficacy and Security of Thymoglobuline in cadaveric donor Efficacy: To demonstrate that in cadaveric donor, Thymoglobuline diminished graft alloreactivity by decreasing expression of inflammatory markers in graft biopsies Security:To demonstrate that the administration of Thymoglobulin does not have side effects in renal recipients.

Conditions

  • Prevention of Kidney Injury Associated With Brain Death

Interventions

DRUG

Thymoglobulin

Sponsors & Collaborators

  • Hospital de Santa Maria, Portugal

    collaborator OTHER

  • Instituto de Investigación Hospital Universitario La Paz

    lead OTHER

Principal Investigators

  • Carlos Jimenez, MD, PhD · Hospital Universitario La Paz

  • Maria Lopez-Oliva, MD · Hospital Universitario La Paz

  • Rui Mayo, MD · Hospital Santa Maria, Portugal

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Portugal
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01939171 on ClinicalTrials.gov